Observational studyClinical rheumatology2026
Efficacy and safety of belimumab in lupus nephritis: a real-world retrospective observational study stratified by treatment phase and age.
Observational study in Clinical rheumatology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
objectivesThis study aims to evaluate the efficacy and safety of adjunctive Belimumab therapy compared to standard therapy alone in patients with lupus nephritis (LN) within a real-world clinical setting.
methodsThis single-center, retrospective observational study included patients with LN from January 2020 to December 2023. A total of 64 patients received belimumab as an adjunct to standard therapy. Patients were stratified into induction and maintenance treatment groups by renal remission status at belimumab initiation. A matched control group (n = 64) with comparable baseline characteristics was established. Clinical efficacy and safety were assessed by disease activity, glucocorticoid tapering, renal and extra-renal relapse rates, and treatment-emergent adverse events.
resultsDuring the induction phase in patients with LN, belimumab did not significantly enhance remission rates within the first six months. However, during maintenance therapy, belimumab effectively reduced disease activity, facilitated glucocorticoid tapering, and significantly decreased renal relapse rates. Furthermore, belimumab increased the cumulative rate of complete renal remission, improved lupus low disease activity state achievement, and slowed the decline in estimated glomerular filtration rate, with a more pronounced benefit observed in adolescents. The overall incidence of adverse events was comparable between the belimumab and control groups, whereas treatment-related comorbidities were reduced in the belimumab group.
conclusionBelimumab demonstrates a favorable safety profile and contributes to the long-term management of LN, particularly in adolescents. These findings support its potential role as an effective adjunctive therapy for LN. Key Points • Belimumab significantly reduces renal relapse, facilitates glucocorticoid tapering, and helps preserve long-term renal function in lupus nephritis maintenance therapy. • Adolescent patients with lupus nephritis represent a key subgroup that derives pronounced therapeutic advantages from adjunctive belimumab treatment. • Belimumab is associated with fewer treatment-related comorbidities compared to standard therapy alone, supporting its safety in real-world use.
Indexed as
Identifiers
41811653What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.